Protalix PRX-102: Likely Approval Could Be A Game Changer By: TalkMarkets May 02, 2022 at 10:02 AM EDT Protalix's PRX-102 drug stands a good chance of being accepted against Fabry disease, with three P3 trials delivering good results. Read More >> Related Stocks: Pfizer Protalix Biotherapeutics
